Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

EPRX Eupraxia Pharmaceuticals Inc

3,1039

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 13:00:00

Verzögert um 15 Minuten

Form D - Notice of Exempt Offering of Securities

Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Eupraxia Pharmaceuticals Charts.

Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Eupraxia Pharmaceuticals Charts.

News Eupraxia Pharmaceuticals Inc

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 20 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Mittwoch 20 November 2024 (2 Monate vor) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 14 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Donnerstag 14 November 2024 (2 Monate vor) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Mittwoch 13 November 2024 (2 Monate vor) • PR Newswire (Canada)

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Dienstag 12 November 2024 (2 Monate vor) • PR Newswire (US)

Form D - Notice of Exempt Offering of Securities
Freitag 8 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 7 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Donnerstag 7 November 2024 (2 Monate vor) • PR Newswire (US)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
Donnerstag 7 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Freitag 1 November 2024 (2 Monate vor) • PR Newswire (US)

Weitere Eupraxia Pharmaceuticals Inc News-Artikel

Royal Canadian Mint Cana...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen